Gene therapy for haemophilia

Bibliography

• CONNELLY S, KALEKO M: Gene therapy for hemophilia A. Thromb. Haemosl (1997) 78(1):31–36.
   PubMed Web of Science ®Google Scholar
• •A recent and excellent review of gene therapy for haemo-philia A.
   Google Scholar
• HOYER LW: Hemophilia A. New Engl. J. Med. (1994) 330(1):38–47.
   Google Scholar
• •Excellent review of haemophilia A and factor VIII.
   Google Scholar
• EISENSMITH RC, WOO SLC: Viral vector-mediated gene therapy for haemophilia B. Thromb. Haemost. (1997) 78(1):24–30.
   PubMed Web of Science ®Google Scholar
• •A recent and excellent review of gene therapy for haemo-philia B.
   Google Scholar
• THOMPSON AR: Structure, function, and molecular defects of factor IX. Blood (1986) 67 (3) :565–572.
   PubMed Web of Science ®Google Scholar
• •Excellent review of factor IX.
   Google Scholar
• CHOO KH, GOULD KG, REES DJG, BROWNLEE GG: Mo-lecular cloning of the gene for human anti-haemophilic factor IX. Nature (1982) 299:178–180.
   PubMed Web of Science ®Google Scholar
• KURACHI K, DAVIE EW: Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl. Acad. ScL USA (1982) 79:6461–6464.
   PubMed Web of Science ®Google Scholar
• ANSON DS, CHOO KH, REES DJG eta].: The gene structure of human anti-haemophilic factor IX. EMBO J. (1984) 3 (5) :1053–1060.
   Google Scholar
• KURACHI K, FURUKAWA M, YAO SN: Biology of factor IX. Blood Cavil]. Fibrinol (1993) 4:953–972.
   PubMed Web of Science ®Google Scholar
• WOOD WI, CAPON DJ, SIMONSEN CC et al.: Expression of active human factor VIII from recombinant DNA clones. Nature (1984) 312:330–337.
   Google Scholar
• VEHAR GA, KEYT B, EATON D et al.: Structure of human factor VIII. Nature (1984) 312:337–342.
   PubMed Web of Science ®Google Scholar
• TOOLE JJ, KNOPF JL, WOZNEY JM eta].: Molecular clon-ing of a cDNA encoding human antihaemophilic factor. Nature (1984) 312:342–347.
   Google Scholar
• KAUFMAN RJ: Biological regulation of factor VIII activ-ity. Ann. Rev. Med. (1992) 43:325–339.
   PubMed Web of Science ®Google Scholar
• VEHAR GA, LAWN RM, TUDDENHAM EGD, WOOD WI: fac-tor VIII and Factor V: biochemistry and pathophysiol-ogy. In: The Metabolic Basis of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Vale D (Eds.), McGraw-Hill, New York (1989).
   Google Scholar
• HEDNER U, DAVIE EW: Introduction to hemostasis and the vitamin K-dependent coagulation factors. In: The Metabolic Basis of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Vale D (Eds.), McGraw-Hill, New York (1989).
   Google Scholar
• BI L, LAWLER AM, ANTONARAKIS SE: Targeted disruption of the mouse Factor VIII gene produces a model of hae-mophilia A. Nature Genetics (1995) 10:119–121.
   PubMed Web of Science ®Google Scholar
• WANG L, ZOPPE M, LEE KF, VERMA IM: A Factor IX-deficient mouse model for hemophilia B gene therapy. International Symposium on Gene Therapy for Hemophilia. Chapel Hill, USA (1997).
   Google Scholar
• SMITH TAG: Gene therapy for haemophilia. Exp. Opin.Invest. Drugs (1995) 4(9):833–842.
   Google Scholar
• KINGDON HS: Gene therapy avoidance: implanting al-logeneic cells within a device. International Symposium on Gene Therapy for Hemophilia. Chapel Hill, USA (1997).
   Google Scholar
• YANG Y, LI Q, ERTL HCJ, WILSON JM: Cellular and humo-ral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant ad-enoviruses. j Vim]. (1995) 69(4) :2004–2015.
   Web of Science ®Google Scholar
• CONNELLY S, ANDREWS JL, GALLO AM et al.: Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. (Submitted).
   Google Scholar
• A recent study demonstrating sustained phenotypic correc-tion of murine haemophilia A.
   Google Scholar
• DAI Y, SETHI E, JOSEPHS S, ALEMANY R, ZHANG W: High level in vivo expression of human full length Factor VIII cDNA in hemophilia A mice by using a mini-adenoviral vector with deletion of all adenoviral genes. Interna-tional Symposium on Gene Therapy for Hemophilia. Chapel Hill, USA (1997).
   Google Scholar
• CONNELLY S, MOUNT J, MAUSER A et al.: Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood (1996) 88(10):3846–3853.
   PubMed Web of Science ®Google Scholar
• •Demonstrates phenotypic correction of canine haemophilia A.
   Google Scholar
• CARTER BJ: The promise of adeno-associated virus vec-tors. Nature Biotechnol (1996) 14:1725–1726.
   Google Scholar
• KOTIN RM: Prospects for the use of adeno-associated vi-rus as a vector for human gene therapy. Human Gene Ther. (1994) 5:793–801.
   PubMed Web of Science ®Google Scholar
• HERZOG RW, HAGSTROM JN, KUNG S et al.: Stable gene transfer and expression of human blood coagulation Factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. ScL USA (1997) 94:5804–5809.
   PubMed Web of Science ®Google Scholar
• •Demonstrates sustained expression of Factor IX following im. delivery of an rAAV vector.
   Google Scholar
• SNYDER RO, MIAO CH, PATIJN GA et al.: Persistent and therapeutic concentrations of human Factor IX in mice after hepatic gene transfer of recombinant AAV vec-tors. Nature Genetics (1997) 16:270–276.
   PubMed Web of Science ®Google Scholar
• •Demonstrates sustained expression of Factor IX following hepatic delivery of an rAAV vector.
   Google Scholar
• GREENGARD JS, BODNER M, MCCORMACK J et al.: Sustained high level Factor VIII expression in immuno-competent rabbits and dogs following peripheral intravenous injection of retroviral vector. International Symposium on Gene Therapy for Hemophilia. Chapel Hill, USA (1997).
   Google Scholar
• •Intriguing report showing efficacy of retroviral-mediated in vivo gene transfer of Factor VIII.
   Google Scholar
• LEVER AML: Editorial. Gene Ther. (1996) 3:470–471.
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GAGE FH, TRONO D, VERMA IM:Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA (1996) 93:11382–11388.
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al: In vivo gene deliv-ery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263–267.
   PubMed Web of Science ®Google Scholar
• BLOMER U, NALDINI L, KAFRI T et al.: Highly efficient and sustained gene transfer in adult neurons with a lentivi-rus vector. J. Vim]. (1997) 71 (9):6641–6649.
   Web of Science ®Google Scholar
• NALDINI L, SONG J, KELLY M et al.: Lentiviral vectors for in vivo gene delivery. International Symposium on Gene Therapy for Hemophilia. Chapel Hill, USA (1997).
   Google Scholar
• DEDIEU J, VIGNE E, TORRENT C et al: Long-term gene de-livery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. j Virol. (1997) 71 (6):4626–4637.
   PubMed Web of Science ®Google Scholar
• WANG Q, GREENBURG G, BUNCH D, FARSON D, FINER MH: Persistent transgene expression in mouse liver fol-lowing in vivo gene transfer with a AE1/AE4 adenovirus vector. Gene Ther. (1997) 4:393–400.
   PubMed Web of Science ®Google Scholar
• CHEN H, MACK LM, KELLY R et al.: Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA (1997) 94:1645–1650.
   PubMed Web of Science ®Google Scholar
• ROY S, SHIRLEY PS, MCCLELLAND A, KALEKO M: Circum-vention of immunity to the adenovirus major coat pro-tein hexon. (Submitted).
   Google Scholar
• SMITH TAG, WHITE BD, GARDNER JM, KALEKO M, MCCLELLAND A: Transient immunosuppression per-mits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. (1996) 3:496–502.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, SMITH AE: Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to re-administer adenoviral vec-tor to the mouse lung. Human Gene Ther. (1997) 8:1095–1104.
   PubMed Web of Science ®Google Scholar
• YANG Y, GREENOUGH K, WILSON JM: Transient immune blockade prevents formation of neutralising antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. (1996) 3:412–420.
   PubMed Web of Science ®Google Scholar
• KAY MA, HOLTERMAN A, MEUSE L et al: Long-term he-patic adenovirus-mediated gene expression in mice fol-lowing CTLA4Ig administration. Nature Genetics (1995) 11:191–197.
   PubMed Web of Science ®Google Scholar
• KAY MA, MEUSE L, GOWN AM et al.: Transient immuno-modulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Nati Acad. Sci. USA (1997) 94:4686–4691.
   PubMed Web of Science ®Google Scholar
• YANG Y, SU Q, GREWAL IS et al.: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. (1996) 70(9):6370–6377.
   PubMed Web of Science ®Google Scholar
• SCARIA A, ST. GEORGE JA, GREGORY RJ eta].: Antibody to CD40 ligand inhibits both humoral and cellular im-mune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther. (1997) 4:611–617.
   Google Scholar